Strong clinical progress in AML and CNS programs, with iadademstat showing high response rates and vafidemstat advancing toward Phase III in BPD. Financial position strengthened by a €12M capital raise and a €25M future investment commitment from COFIDES.Original document: Oryzon Genomics SA [ORY…
MADRID and CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today reported financial results for the three months ended June 30, 2026, and provided a corporate upd…
MADRID and CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code:ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12…
